The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk.
The β-amyloid peptide may play a central role in Alzheimer's disease (AD) pathogenesis. We have evaluated variants in seven Aβ-degrading genes (ACE, ECE1, ECE2, IDE, MME, PLAU, and TF) for association with AD risk in the Genetic and Environmental Risk in Alzheimer's Disease Consortium 1 (GERAD1) cohort, and with three cognitive phenotypes in the Lothian Birth Cohort 1936 (LBC1936), using 128 and 121 SNPs, respectively. In GERAD1, we identified a significant association between a four-SNP intragenic ECE1 haplotype and risk of AD in individuals that carried at least one APOE ε4 allele (P = 0.00035, odds ratio = 1.61). In LBC1936, we identified a significant association between a different two-SNP ECE1 intragenic haplotype and non-verbal reasoning in individuals lacking the APOE ε4 allele (P = 0.00036, β = -0.19). Both results showed a trend towards significance after permutation (0.05 < P < 0.10). A follow-up cognitive genetic study evaluated the association of ECE1 SNPs in three additional cohorts of non-demented older people. Meta-analysis of the four cohorts identified the significant association (Z < 0.05) of SNPs in the ECE-1b promoter with non-verbal reasoning scores, particularly in individuals lacking the APOE ε4 allele. Our genetic findings are not wholly consistent. Nonetheless, the AD associated intronic haplotype is linked to the 338A variant of known ECE1b promoter variant, 338C>A (rs213045). We observed significantly less expression from the 338A variant in two human neuroblastoma cell lines and speculate that this promoter may be subject to tissue-specific regulation.
Medical Genetics, Molecular Medicine Centre, University of Edinburgh, Edinburgh, UK. g.hamilton@ed.ac.uk
Gillian
G
Hamilton
Sarah E
SE
Harris
Gail
G
Davies
David C
DC
Liewald
Albert
A
Tenesa
Antony
A
Payton
Michael A
MA
Horan
William E R
WE
Ollier
Neil
N
Pendleton
John M
JM
Starr
David
D
Porteous
Ian J
IJ
Deary
D000368:Aged; D000375:Aging / Q000235:genetics* / Q000473:pathology; D000544:Alzheimer Disease / Q000235:genetics* / Q000503:physiopathology*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016282:Aspartic Acid Endopeptidases / Q000235:genetics*; D003071:Cognition; D015331:Cohort Studies; D000072396:Endothelin-Converting Enzymes; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008666:Metalloendopeptidases / Q000235:genetics*; D008875:Middle Aged; D009483:Neuropsychological Tests; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics; D059748:Proteolysis; D012307:Risk Factors
D016229:Amyloid beta-Peptides; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; C000606924:ECE2 protein, human; D000072396:Endothelin-Converting Enzymes